National Pension Service Increases Stock Position in Johnson & Johnson $JNJ

Key Points

• National Pension Service raised its Johnson & Johnson stake 3.2% in Q3, buying 151,707 shares to hold 4,926,569 shares (about 0.20% of JNJ) valued at $913,484,000, making J&J its 21st-largest holding (~0.7% of the fund).
• Analysts have grown more bullish recently—Wells Fargo and Wolfe Research lifted targets to $240 (Scotiabank to $265)—and the consensus rating is "Moderate Buy" with a $233.05 price target.
• J&J reported Q4 EPS of $2.46 (in line) and revenue of $24.56B (beat), set FY2026 guidance of 11.430–11.630 EPS, announced a $1.30 quarterly dividend (2.3% yield), and faces mixed catalysts including a CHMP positive opinion for AKEEGA, a dismissed fraud suit but ongoing talc litigation risk, and recent CEO insider selling (~$22M).

National Pension Service raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 4,926,569 shares of the company's stock after purchasing an additional 151,707 shares during the period. Johnson & Johnson comprises approximately 0.7% of National Pension Service's portfolio, making the stock its 21st biggest holding. National Pension Service owned 0.20% of Johnson & Johnson worth $913,484,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SOA Wealth Advisors LLC. increased its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company's stock valued at $1,371,000 after acquiring an additional 53 shares during the last quarter. Ethos Financial Group LLC boosted its stake in Johnson & Johnson by 0.6% during the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company's stock valued at $1,689,000 after purchasing an additional 53 shares during the period. Heritage Oak Wealth Advisors LLC grew its holdings in Johnson & Johnson by 3.5% in the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company's stock worth $304,000 after buying an additional 55 shares in the last quarter. Investor s Fiduciary Advisor Network LLC increased its holdings in shares of Johnson & Johnson by 0.8% during the third quarter. Investor s Fiduciary Advisor Network LLC now owns 6,905 shares of the company's stock valued at $1,280,000 after purchasing an additional 55 shares during the period. Finally, Lifestyle Asset Management Inc. lifted its stake in shares of Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company's stock worth $312,000 after acquiring an additional 56 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on JNJ. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an "overweight" rating in a research note on Thursday, January 22nd. Wolfe Research upped their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a report on Monday, January 5th. BMO Capital Markets reiterated an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Freedom Capital downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. Finally, Raymond James Financial raised their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an "outperform" rating in a research note on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $233.05.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CHMP (European regulator) issued a positive opinion for AKEEGA (niraparib + abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer — regulatory progress supports a new oncology revenue stream and raises upside to J&J’s pharma growth outlook. Read More.
• Positive Sentiment: Daiwa Capital Markets raised its JNJ price target to $237 and kept an Outperform rating, signaling buy-side confidence in near-term upside. Read More.
• Positive Sentiment: Morgan Stanley upgraded J&J citing a stronger growth outlook; that upgrade (and related coverage noting fresh annual highs) helped lift sentiment earlier in the session. Read More.
• Positive Sentiment: Scotiabank raised its target to $265 after J&J’s solid quarterly results and reiterated Outperform — another signals of analyst bullishness post-Q4. Read More.
• Neutral Sentiment: Wall Street coverage is broadly positive but measured — several outlets summarized consensus analyst targets and noted JNJ’s strong 12‑month performance; analysts remain cautiously optimistic rather than uniformly exuberant. Read More.
• Neutral Sentiment: Unusually high options volume was reported, indicating elevated trader interest and potential short‑term volatility; this is activity-driven rather than a directional fundamental change. Read More.
• Positive Sentiment: A U.S. judge dismissed a fraud lawsuit over J&J’s talc bankruptcy strategy, removing one near-term legal overhang — a favorable court outcome for liability risk. Read More.
• Negative Sentiment: Analysts and legal commentators warn the talc saga isn’t fully settled — a Seeking Alpha piece cautions that dismissal of a fraud claim doesn’t end broader talc litigation, keeping potential legal risk on the radar. Read More.
• Negative Sentiment: Insider selling: reports show the CEO sold roughly $22M in shares after Q4 results — raises governance/perception questions for some investors despite company explanations. Read More.

Johnson & Johnson Stock Down 0.1%

Shares of JNJ opened at $227.10 on Monday. The business's 50 day simple moving average is $210.72 and its 200-day simple moving average is $191.76. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $547.16 billion, a P/E ratio of 20.55, a PEG ratio of 2.21 and a beta of 0.35. Johnson & Johnson has a one year low of $141.50 and a one year high of $230.00.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting analysts' consensus estimates of $2.46. The company had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company's revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson's dividend payout ratio is currently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.